Intellia Therapeutics (NTLA) Cash from Investing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash from Investing Activities data on file, last reported at $66.3 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $66.3 million, down 29.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $200.0 million (down 6.53% YoY), and the FY2025 annual result was $228.0 million, up 81.6% from the prior year.
• Cash from Investing Activities grew to $66.3 million in Q1 2026 per NTLA's latest filing, from $27.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $151.6 million in Q4 2024 and troughed at -$122.2 million in Q1 2023.
• A 5-year average of $32.3 million and a median of $45.9 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities sank 357.51% in 2023, then surged 1498.51% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$30.2 million in 2022, then jumped by 252.36% to $45.9 million in 2023, then jumped by 229.93% to $151.6 million in 2024, then plunged by 81.83% to $27.5 million in 2025, then soared by 140.83% to $66.3 million in 2026.
• Business Quant data shows NTLA's Cash from Investing Activities at $66.3 million in Q1 2026, $27.5 million in Q4 2025, and -$741000.0 in Q3 2025.